96 SKIN MICROBIOME
product to bioselectively target S. aureus by using metagenomic analysis, which involves analyzing bacterial populations on the host’s skin. Solabia partnered with a dermatological
clinic to conduct a study involving a group of 22 Caucasian children aged from three to 11 with mild to moderate atopic dermatitis (SCORAD index <40).
The participants were divided into two
groups: one group applying a placebo and the other applying a cream containing the postbiotic glycolipid, noting that both formulas have been enriched with 10% of shea butter to adapt for application on compromised skin and ensure volunteers comfort during the clinical study. The product was applied twice daily to all
lesional areas as well as the surrounding non- lesional areas, and samples were collected from the most representative lesional areas of the SCORAD.
The initial evaluation involved calculating
the Shannon index to measure species diversity within the skin microbiota, with a higher index indicating greater diversity. After extracting 16S rRNA (16S ribosomal ARN), and performing PCR amplification, similar sequences were grouped into operational taxonomic units. Bioinformatics tools were then used for
bacterial identification. Results showed that the postbiotic glycolipid increased the Shannon index compared to both day 0 and the placebo in lesional and non-lesional areas (Figure 3), demonstrating its efficacy in promoting microbial diversity and balance. To go deeper, a metagenomic study on the
Staphyloccoci species is performed. Atopic- prone skin condition is characterized by an increase in Staphylococci species, which should be decreased to restore the normal state of the skin. At D0, a high amount of S. aureus was
clearly observed. After 28 days, the postbiotic glycolipid drastically reduced S. aureus by 93%, and reduced the overall Staphylococcus family, which can be opportunistic and harmful to the skin. In non-lesional areas of atopic skin, where
S. aureus was present in small quantities, the postbiotic glycolipid reduced also drastically the amount of opportunistic S. aureus by 84% to prevent further colonization under harmful conditions, while preserving the rest of the Staphylococci species (Figure 4). This demonstrated the bioselective
effect on S. aureus without impacting other species. These findings indicate that the active ingredient has a curative effect on atopic-prone skin, as well as a potential preventive effect on healthy skin. Furthermore, the dermatologist assessed
atopic signs using the SCORAD (SCORing Atopic Dermatitis) index, an international tool recognized and employed by dermatologists to evaluate the extent and severity of atopic dermatitis. The SCORAD index encompasses three
components with both objective and subjective criteria: the extent of skin involvement (A), the intensity of six specific items (B) including erythema, oedema/papules, oozing/crust,
PERSONAL CARE October 2024 SCORAD Index Atopic clinical signs
vs Placebo -48%*
-30%* Redness
Scratch marks vs Placebo
#p<0.1 and
*p<0.05 -15%# vs Placebo Placebo Placebo ■ Serenibiome ■ -19%# vs Placebo Serenibiome
Erythema ■ Excoriation ■ Others* ■ * Others: oedema/papules, oozing crust, Lichenification, dryness
Figure 5: SCORAD index and atopic clinical signs evaluation
excoriation, lichenification, and dryness, and subjective symptoms (C) such as pruritus and sleep loss. The results demonstrated a reduction in the
SCORAD index for all the volunteers after 28 days; however, the group that used the cream containing the postbiotic glycolipid showed a significant improvement compared to the placebo.
This improvement could be correlated with
the bioselective effect of the active ingredient, which drastically reduced S. aureus, a marker of AD. Additionally, a significant decrease of 30% in redness compared to placebo, a 48% significant decrease in scratch marks compared to placebo, and reductions in other atopic signs were observed, indicating the active ingredient’s efficacy in alleviating atopic conditions (Figure 5).
Conclusion The integration of microbiome-targeted routines marks a transformative approach in skincare, emphasizing the essential role of microbial balance in maintaining skin health and managing conditions like atopic dermatitis (AD). Through in vitro and in vivo studies, investigation into the postbiotic glycolipid derived from Pseudozyma flocculosa has yielded promising results. Preclinical findings underscore the
postbiotic glycolipid’s ability to selectively inhibit S. aureus while preserving commensal S. epidermidis populations. This targeted action not only rebalances the skin microbiota but also mitigates inflammatory skin condition and supports skin barrier repair. Clinical trials further validate these
outcomes, demonstrating significant improvements in microbial diversity and reductions in S. aureus colonization among individuals with mild to moderate AD. In parallel, subjective assessments using the SCORAD index reveal notable decreases in atopic signs, including erythema and excoriation, highlighting
the postbiotic’s restorative potential. Moving forward, the development of such
bioinspired active ingredients presents a perfect shift in skincare innovation, promising enhanced efficacy and safety profiles compared to conventional skin routines. By harnessing the symbiotic relationship between the human body and its microbiome, these advancements address current cosmetic challenges and offer effective solutions for skin issue. In conclusion, the research presented
here not only elucidates the intricate interplay between the skin microbiome and dermocosmetological health but also underscores the potential of microbiome- targeted routines in redefining skincare practices for sensitive and atopic skin conditions.
References 1. Woodby B, Penta K, Pecorelli A, Lila MA, Valacchi G. Skin Health from the Inside Out. Annual Review of Food Science and Technology. 2020; Mar 25;11(1):235–54
2. Pistone D, Meroni G, Panelli S, D’Auria E, Acunzo M, Pasala AR et al. A Journey on the Skin Microbiome: Pitfalls and Opportunities. International Journal of Molecular Sciences. 2021; Sep 12;22(18):9846
3. Carmona-Cruz S, Orozco-Covarrubias L, Sáez-de-Ocariz M. The Human Skin Microbiome in Selected Cutaneous Diseases. Frontiers in Cellular and Infection Microbiology. 2022; Mar 7;12
4. Misery L, Loser K, Ständer S. Sensitive skin. Journal of the European Academy of Dermatology and Venereology. 2016; Jan 25;30:2–8
5. Chen W, Dai R, Li L. The prevalence of self- declared sensitive skin: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(8):1779-1788
6. Deng L, Costa F, Blake KJ et al. S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis. Cell. 2023;186(24):5375-5393.e25
www.personalcaremagazine.com
PC
Δ Scorad Index vs D0
Δ Intensity vs D0
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108
